JP2011511949A - 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ - Google Patents

肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ Download PDF

Info

Publication number
JP2011511949A
JP2011511949A JP2010546779A JP2010546779A JP2011511949A JP 2011511949 A JP2011511949 A JP 2011511949A JP 2010546779 A JP2010546779 A JP 2010546779A JP 2010546779 A JP2010546779 A JP 2010546779A JP 2011511949 A JP2011511949 A JP 2011511949A
Authority
JP
Japan
Prior art keywords
alk
probe
inversion
chromosome
eml4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010546779A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011511949A5 (enExample
Inventor
リー，チャールズ
マーフィー，カーリー
ジャンネ，パシ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of JP2011511949A publication Critical patent/JP2011511949A/ja
Publication of JP2011511949A5 publication Critical patent/JP2011511949A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/533—Production of labelled immunochemicals with fluorescent label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2010546779A 2008-02-12 2009-02-12 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ Pending JP2011511949A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6542208P 2008-02-12 2008-02-12
PCT/US2009/000879 WO2009102446A2 (en) 2008-02-12 2009-02-12 Fish assay for eml4 and alk fusion in lung cancer

Publications (2)

Publication Number Publication Date
JP2011511949A true JP2011511949A (ja) 2011-04-14
JP2011511949A5 JP2011511949A5 (enExample) 2012-03-29

Family

ID=40957428

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010546779A Pending JP2011511949A (ja) 2008-02-12 2009-02-12 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ

Country Status (6)

Country Link
US (1) US20110110923A1 (enExample)
EP (1) EP2255190A4 (enExample)
JP (1) JP2011511949A (enExample)
AU (1) AU2009215168A1 (enExample)
CA (1) CA2715380A1 (enExample)
WO (1) WO2009102446A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021035925A (ja) * 2019-08-30 2021-03-04 学校法人同志社 Ｅｍｌ４−ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP2022543594A (ja) * 2019-08-05 2022-10-13 北京基石生命科技有限公司 肺がん固形腫瘍の初代細胞と肺がん胸水の初代腫瘍細胞の培養方法およびキット
WO2023282488A1 (ko) * 2021-07-08 2023-01-12 가톨릭대학교 산학협력단 암 세포 판정을 위한 핵이미지 선별 장치 및 핵이미지 선별 방법

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
ES2561406T3 (es) 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP3546596B1 (en) 2009-05-26 2022-05-11 Quest Diagnostics Investments Incorporated Use of a kit for detecting gene dysregulations
US8546552B2 (en) 2009-12-23 2013-10-01 Quest Diagnostics Investments Incorporated TMPRSS2 for the diagnosis of prostate disease
AR080913A1 (es) * 2010-04-16 2012-05-16 Response Genetics Cebadores, sondas, metodos y conjuntos de elementos para la deteccion de variantes de eml4- alk
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
EP2670867B1 (en) * 2011-02-04 2017-11-01 The Trustees Of The University Of Pennsylvania A method for detecting chromosome structure and gene expression simultaneously in single cells
DE102011100242A1 (de) * 2011-05-02 2012-11-08 Zytovision Gmbh Verfahren zur Detektion von Chromosomenaberration
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2714038A1 (en) 2011-05-24 2014-04-09 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors
CA3113672A1 (en) 2011-07-01 2013-01-10 Htg Molecular Diagnostics, Inc. Methods of detecting gene fusions
EP2729144A2 (en) * 2011-07-07 2014-05-14 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
WO2013074594A1 (en) 2011-11-14 2013-05-23 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
DK2838998T3 (en) 2012-04-18 2018-01-15 Cell Signaling Technology Inc EGFR AND ROS1 IN CANCER
AU2013204563B2 (en) 2012-05-05 2016-05-19 Takeda Pharmaceutical Company Limited Compounds for inhibiting cell proliferation in EGFR-driven cancers
WO2013170182A1 (en) 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
RU2509153C1 (ru) * 2012-11-28 2014-03-10 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Способ анализа транслокаций eml4-alk, ассоциированных с чувствительностью рака легкого к противоопухолевой таргетной терапии
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
EA033304B1 (ru) 2014-02-04 2019-09-30 Астеллас Фарма Инк. Фармацевтическая композиция, включающая диамино-гетероциклическое карбоксамидное соединение в качестве активного ингредиента
JP2018504446A (ja) 2015-02-09 2018-02-15 シンタ ファーマシューティカルズ コーポレーション がんを処置するためのｈｓｐ９０阻害剤およびｐｄ−１阻害剤の組み合わせ治療
CN105368962A (zh) * 2015-12-18 2016-03-02 河南赛诺特生物技术有限公司 肺癌alk基因重排快速检测荧光探针及制备方法
CN105543353A (zh) * 2015-12-30 2016-05-04 广州安必平医药科技股份有限公司 Alk基因和eml4基因检测探针及其制备方法和试剂盒
JP6728503B2 (ja) 2017-02-24 2020-07-22 テグ−キョンプク メディカル イノベーション ファウンデーション 血液脳関門を通過することができる化合物を有効成分として含有する脳腫瘍の予防または治療用薬学的組成物
CN108998503B (zh) * 2018-08-17 2022-04-05 中山康源基因技术科技有限公司 一种Oligo探针及其制备方法与应用
CN110066876A (zh) * 2019-06-06 2019-07-30 徐州医科大学 一种用于癌症诊断的分子标志物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005304508A (ja) * 1989-12-01 2005-11-04 Regents Of The Univ Of California 染色体−特異的染色の方法および組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756696A (en) * 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5447841A (en) * 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) * 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US6344315B1 (en) * 1986-01-16 2002-02-05 The Regents Of The University Of California Chromosome-specific staining to detect genetic rearrangements associated with chromosome 3 and/or chromosome 17
US5491224A (en) * 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US6573043B1 (en) * 1998-10-07 2003-06-03 Genentech, Inc. Tissue analysis and kits therefor
US7288529B2 (en) * 2003-04-24 2007-10-30 New York University ALK protein tyrosine kinase, cells and methods embodying and using same
US8062897B2 (en) * 2003-07-21 2011-11-22 Aureon Laboratories, Inc. Diagnostic histopathology using multiplex gene expression FISH
JP3884462B2 (ja) * 2005-10-14 2007-02-21 株式会社ファースト 高速画像探索方法
ES2561406T3 (es) * 2006-04-14 2016-02-26 Cell Signaling Technology, Inc. Defectos de genes y quinasa ALK mutante en tumores sólidos humanos
EP1914240B1 (en) * 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
JP5562640B2 (ja) * 2007-04-13 2014-07-30 セル・シグナリング・テクノロジー・インコーポレイテツド ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005304508A (ja) * 1989-12-01 2005-11-04 Regents Of The Univ Of California 染色体−特異的染色の方法および組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6013057522; Ｓｏｄａ　Ｍ　ｅｔ　ａｌ: 'Ｉｄｅｎｔｉｆｉｃａｔｉｏｎ　ｏｆ　ｔｈｅ　ｔｒａｎｓｆｏｒｍｉｎｇ　ＥＭＬ４-ＡＬＫ　ｆｕｓｉｏｎ　ｇｅｎｅ　ｉｎ　ｎｏｎ-ｓｍａｌｌ-ｃｅｌｌ　ｌｕｎｇ　ｃａｎｃｅｒ' Ｎａｔｕｒｅ ４４８（７１５３）, 20070802, ５６１-５６６ *
JPN6013057525; Ｇａｓｃｏｙｎｅ　ＲＤ　ｅｔ　ａｌ: 'ＡＬＫ-ｐｏｓｉｔｉｖｅ　ｄｉｆｆｕｓｅ　ｌａｒｇｅ　Ｂ-ｃｅｌｌ　ｌｙｍｐｈｏｍａ　ｉｓ　ａｓｓｏｃｉａｔｅｄ　ｗｉｔｈ　Ｃｌａｔｈｒｉｎ-ＡＬＫ　ｒｅａｒｒａｎｇｅｍｅｎｔｓ：　ｒｅｐｏｒｔ　ｏｆ' Ｂｌｏｏｄ １０２（７）, 20031001, ２５６８-２５７３ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022543594A (ja) * 2019-08-05 2022-10-13 北京基石生命科技有限公司 肺がん固形腫瘍の初代細胞と肺がん胸水の初代腫瘍細胞の培養方法およびキット
JP7510998B2 (ja) 2019-08-05 2024-07-04 北京基石生命科技有限公司 肺がん固形腫瘍の初代細胞と肺がん胸水の初代腫瘍細胞の培養方法およびキット
JP2021035925A (ja) * 2019-08-30 2021-03-04 学校法人同志社 Ｅｍｌ４−ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
JP7385191B2 (ja) 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
WO2023282488A1 (ko) * 2021-07-08 2023-01-12 가톨릭대학교 산학협력단 암 세포 판정을 위한 핵이미지 선별 장치 및 핵이미지 선별 방법

Also Published As

Publication number Publication date
CA2715380A1 (en) 2009-08-20
WO2009102446A3 (en) 2009-11-26
EP2255190A2 (en) 2010-12-01
AU2009215168A1 (en) 2009-08-20
EP2255190A4 (en) 2011-05-04
WO2009102446A2 (en) 2009-08-20
US20110110923A1 (en) 2011-05-12

Similar Documents

Publication Publication Date Title
JP2011511949A (ja) 肺癌におけるｅｍｌ４とａｌｋの融合のためのｆｉｓｈアッセイ
JP6781184B2 (ja) がん転移の予後診断および処置のための方法
JP7369672B2 (ja) Ｅｇｆｒ－標的製剤に対する感受性予測用の新規なバイオマーカー及びその用途
AU2014229505B2 (en) Method for the prognosis and treatment of cancer metastasis
ES2705237T3 (es) Método para el diagnóstico y el pronóstico de metástasis del cáncer de pulmón
JP6074049B2 (ja) ｃ−ＭＡＦを用いた前立腺がん転移の診断、予後診断および処置のための方法
EP3325661B1 (en) Fgfr expression and susceptibility to an fgfr inhibitor
KR20140047138A (ko) Ｋｉｆ5ｂ 유전자와 ｒｅｔ 유전자와의 융합 유전자, 및 당해 융합 유전자를 표적으로 한 암 치료의 유효성을 판정하는 방법
EP3070177A1 (en) Method for predicting long-term efficacy of vegf inhibitor
Huang et al. HPV enhances HNSCC chemosensitization by inhibiting SERPINB3 expression to disrupt the fanconi anemia pathway
CN106999592A (zh) 泛fgfr抑制剂的用途及鉴定患有适于用泛fgfr抑制剂治疗的癌症的患者的方法
Tamkovich et al. Circulating DNA in the blood and its application in medical diagnosis
WO2013111668A1 (ja) Kif5b遺伝子とret遺伝子との間の転座を検出するfishアッセイ
Kasprzak et al. Expression of various insulin-like growth factor-1 mRNA isoforms in colorectal cancer
US20130237590A1 (en) Assessing thyroid neoplasms
CN114632084B (zh) 联合治疗肺粘液性腺癌的药物
US20190062846A1 (en) Compositions and methods for screening pediatric gliomas and methods of treatment thereof
JP5523103B2 (ja) 第１２染色体における遺伝子異常を含む方法および使用
EP4304572A1 (en) Ep300 degrader and uses thereof in neuroblastoma
WO2022229846A1 (en) Treatment of cancer using a transforming growth factor beta receptor type 1 inhibitor
CN117651869A (zh) 用于治疗癌症的诊断方法和组合物
JP2009011249A (ja) 胃を原発巣とする消化管間質腫瘍の悪性化の診断法
HK1256118B (en) Fgfr expression and susceptibility to an fgfr inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131126

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140225

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140304

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140326

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140402

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140425

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140526

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20141118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20150526